Envestnet Asset Management
VRNA

Envestnet Asset Management’s Verona Pharma VRNA Stock Holding History

Envestnet Asset Management’s Portfolio VRNA Stock Details VRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-3,398
Closed -$363K – 4682
2025
Q3 		$363K Sell
3,398
-53,666
-94% -$5.6M ﹤0.01% 3962
2025
Q2 		$5.4M Buy
57,064
+1,811
+3% +$134K ﹤0.01% 2148
2025
Q1 		$3.51M Sell
55,253
-1,349
-2% -$80.7K ﹤0.01% 2374
2024
Q4 		$2.63M Sell
56,602
-9,472
-14% -$356K ﹤0.01% 2530
2024
Q3 		$1.9M Buy
66,074
+37,483
+131% +$922K ﹤0.01% 2691
2024
Q2 		$413K Buy
28,591
+896
+3% +$13.1K ﹤0.01% 3558
2024
Q1 		$446K Buy
27,695
+2,025
+8% +$35K ﹤0.01% 3516
2023
Q4 		$510K Sell
25,670
-1,978
-7% -$29.2K ﹤0.01% 3316
2023
Q3 		$451K Buy
27,648
+2,990
+12% +$57.6K ﹤0.01% 3309
2023
Q2 		$521K Sell
24,658
-30,753
-55% -$656K ﹤0.01% 3180
2023
Q1 		$445K Buy
55,411
+29,657
+115% +$640K ﹤0.01% 3217
2022
Q4 		$673K Buy
25,754
+9,562
+59% +$127K ﹤0.01% 2919
2022
Q3 		$165K Buy
+16,192
New +$136K ﹤0.01% 3633

Other funds holding VRNA

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Envestnet Asset Management's VRNA Position: Q4 2025 in Review

Envestnet Asset Management sold out of Verona Pharma (VRNA) in Q4 2025, closing a stake of 3,398 shares — an estimated $363K sold.

Envestnet Asset Management first reported a position in VRNA in Q3 2022 and held it in 13 quarters. The position peaked at $5.4M in Q2 2025. 1 fund tracked by Wall St. Rank holds VRNA as of Q4 2025.

  • Envestnet Asset Management reported no remaining Verona Pharma position as of Q4 2025 after selling out during the quarter.
  • Envestnet Asset Management sold 3,398 Verona Pharma shares in Q4 2025, an estimated $363K.
  • Envestnet Asset Management first reported a position in Verona Pharma in Q3 2022 and held it in 13 quarters.
  • Envestnet Asset Management's Verona Pharma position peaked at $5.4M in Q2 2025.
  • 1 fund tracked by Wall St. Rank held Verona Pharma as of Q4 2025.

Based on Envestnet Asset Management's 13F filing for Q4 2025, filed 10 Feb 2026.